热门资讯> 正文
GRI Bio报告第一季度业绩
2026-05-15 02:31
- GRI Bio press release (GRI): Q1 Net loss for the quarter ended March 31, 2026, was approximately $2.0 million, compared to approximately $3.0 million for the same period in 2025
- Cash and cash equivalents totaled approximately $11.0 million as of March 31, 2026, compared to approximately $8.2 million as of December 31, 2025..
More on GRI Bio
- Seeking Alpha’s Quant Rating on GRI Bio
- Historical earnings data for GRI Bio
- Financial information for GRI Bio
风险及免责提示:以上内容仅代表作者的个人立场和观点,不代表华盛的任何立场,华盛亦无法证实上述内容的真实性、准确性和原创性。投资者在做出任何投资决定前,应结合自身情况,考虑投资产品的风险。必要时,请咨询专业投资顾问的意见。华盛不提供任何投资建议,对此亦不做任何承诺和保证。